World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
76
Citations
22299
World Ranking
1904
National Ranking
928

Medicine

D-Index
76
Citations
22296
World Ranking
18748
National Ranking
9341

Albert F. LoBuglio publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Albert F. LoBuglio sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 292 publications — 62nd percentile

62% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Albert F. LoBuglio D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Albert F. LoBuglio sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 76 D-Index — 62nd percentile

62% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Albert F. LoBuglio is affiliated with the University of Alabama at Birmingham in the United States. Their research spans several interconnected fields, including Biochemistry, Genetics and Molecular Biology, as well as Medicine, with a focus on Cancer Research, Genetics, and Oncology as subfields.

The scientist's work frequently explores topics related to Breast Cancer Treatment Studies, the effects of Estrogen and related hormones, and the role of HER2/EGFR in cancer research.

A notable recent publication is titled "TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer," published in 2020 in Breast Cancer Research.

Frequent co-authors collaborating with Albert F. LoBuglio include:

  • Christos Vaklavas
  • Brian S. Roberts
  • Katherine E. Varley
  • Nancy U. Lin
  • Minetta C. Liu

They have published primarily in the venue Breast Cancer Research.

Best Publications

  • Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.

    Ziegler Ej;Fisher Cj;Sprung Cl;Straube Rc

  • Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy

    Myron S. Czuczman;A. J. Grillo-López;C. A. White;M. Saleh

  • Mouse/human chimeric monoclonal antibody in man: kinetics and immune response

    Albert F. Lobuglio;Richard H. Wheeler;John Trang;Amy Haynes

  • Phase I Study of Anti–Epidermal Growth Factor Receptor Antibody Cetuximab in Combination With Radiation Therapy in Patients With Advanced Head and Neck Cancer

    Francisco Robert;Mark P. Ezekiel;Sharon A. Spencer;Ruby F. Meredith

  • Red cells coated with immunoglobulin G: binding and sphering by mononuclear cells in man.

    Albert F. LoBuglio;Ramzi S. Cotran;James H. Jandl

  • Characterization of a messenger RNA polynucleotide vaccine vector

    R. M. Conry;A. F. LoBuglio;M. Wright;L. Sumerel

  • Human immune response to monoclonal antibodies.

    M. B. Khazaeli;Robert M. Conry;Albert F. LoBuglio

  • Human Blood Monocytes: Stimulators of Granulocyte and Mononuclear Colony Formation in vitro

    Unknown

  • Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers

    James A. Bonner;Kevin P. Raisch;Hoa Q. Trummell;Francisco Robert

  • A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer.

    James A. Posey;M. B. Khazaeli;Alma DelGrosso;Mansoor N. Saleh

  • The Small Heat Shock Protein αB-crystallin Is a Novel Inhibitor of TRAIL-induced Apoptosis That Suppresses the Activation of Caspase-3 *

    Merideth C. Kamradt;Merideth C. Kamradt;Meiling Lu;Michael E. Werner;Toni Kwan

  • Phase I Trial of the Anti–Lewis Y Drug Immunoconjugate BR96-Doxorubicin in Patients With Lewis Y–Expressing Epithelial Tumors

    Mansoor N. Saleh;Steve Sugarman;James Murray;Joy B. Ostroff

  • Nuclear localization of KLF4 is associated with an aggressive phenotype in early-stage breast cancer.

    Ashka Y. Pandya;Lynya I. Talley;Andra R. Frost;Thomas J. Fitzgerald

  • Immune Response to a Carcinoembryonic Antigen Polynucleotide Vaccine

    Robert M. Conry;Albert F. LoBuglio;Judith Kantor;Jeffrey Schlom

  • Effects of Corticosteroids on Human Monocyte Function

    Unknown

  • Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model.

    Donald J. Buchsbaum;Tong Zhou;William E. Grizzle;Patsy G. Oliver

  • Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study.

    Ronald D. Alvarez;Edward E. Partridge;M.B. Khazaeli;Gene Plott

  • Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma.

    Mansoor N. Saleh;M. B. Khazaeli;Richard H. Wheeler;Edward Dropcho

  • A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity.

    R M Conry;A F LoBuglio;F Loechel;S E Moore

  • A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia.

    Mansoor N. Saleh;John Gutheil;Melvin Moore;Patty W. Bunch

  • Expression of human endogenous retrovirus k envelope transcripts in human breast cancer.

    Feng Wang-Johanning;Andra R. Frost;Gary L. Johanning;M. B. Khazaeli

  • Cetuximab, a Monoclonal Antibody Targeting the Epidermal Growth Factor Receptor, in Combination With Gemcitabine for Advanced Pancreatic Cancer: A

    Henry Q. Xiong;Arthur Rosenberg;Albert LoBuglio;William Schmidt

Frequent Co-Authors

William E. Grizzle
William E. Grizzle University of Alabama at Birmingham
Jeffrey Schlom
Jeffrey Schlom National Institutes of Health
David T. Curiel
David T. Curiel Washington University in St. Louis
Ronald D. Alvarez
Ronald D. Alvarez Vanderbilt University Medical Center
Robert P. Kimberly
Robert P. Kimberly University of Alabama at Birmingham
William J. Koopman
William J. Koopman University of Alabama at Birmingham
Tong Zhou
Tong Zhou University of Alabama at Birmingham
Kirby I. Bland
Kirby I. Bland University of Alabama at Birmingham
George M. Shaw
George M. Shaw University of Pennsylvania
Richard M. Myers
Richard M. Myers HudsonAlpha Institute for Biotechnology

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in exploring healthcare pathways related to immunology, nursing offers accessible and versatile options. Many students begin by looking into lpn schools easy to get into, which provide foundational knowledge and clinical experience. These programs often serve as a stepping stone to more advanced roles in healthcare.

Nurse practitioners (NPs) specializing in immunology-related fields are in high demand, particularly in mental health and chronic disease management. Prospective students can consider programs known for being the easiest NP program options to help fast-track their education. This flexibility allows learners to balance studies with clinical work effectively.

Online programs for psychiatric nurse practitioners, such as online pmhnp programs with clinical placement, offer valuable hands-on experience in clinical settings. Clinical placements are critical for integrating theory with practice, especially in fields requiring patient interaction.

Cost is another important factor; thus, students often seek the cheapest psych NP programs online to ensure education remains financially accessible while maintaining quality. Affordable programs can significantly reduce student debt and improve career entry opportunities.

Best Scientists Citing Albert F. LoBuglio

Trending Scientists

Recently Published Articles